SL 052

Drug Profile

SL 052

Alternative Names: Nanoparticle formulation of SL052 (for IV administration) - Quest PharmaTech; Photodynamic cancer therapy (SL052) - Quest PharmaTech; SL 052 PDT; SL052

Latest Information Update: 25 Jul 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Quest PharmaTech
  • Developer BC Cancer Agency; National Research Council Canada; Quest PharmaTech; University of Alberta
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Gastrointestinal cancer
  • No development reported Lung cancer

Most Recent Events

  • 25 Jul 2013 SL 052 is still in phase I trials for Prostate cancer in Canada
  • 25 Jul 2013 The nanoparticle formulation of SL 052 appears to still be in preclinical trials in Canada (for Gastrointestinal cancer)
  • 25 Jul 2013 No development reported - Preclinical for Lung cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top